Primary hyperparathyroidism and neuropsychiatric alterations in a nonagenarian woman

Aging Clinical and Experimental Research

Volumn 17, Issue 1, 2005, Pages 67-70

  Prete, Camilla ^a,b   Foppiani, Luca ^b   Trasciatti, Stefane ^a   Senesi, Barbara ^a   Veneziano, Massimo ^a   Barone, Antonella ^a   Palummeri, Ernesto ^a  

^a Galliera Hospital   (United States)

^b GALLIERA HOSPITAL   (Italy)

Author keywords

Behavioral alterations; Bisphosphonates; Elderly; Hypercalcemia; Primary hyperparathyroidism

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PARATHYROID HORMONE; ZOLEDRONIC ACID; DIURETIC AGENT; IMIDAZOLE DERIVATIVE; SODIUM CHLORIDE;

AGED; ANAMNESIS; ARTICLE; BEHAVIOR CHANGE; BONE DENSITOMETRY; CASE REPORT; CEREBROVASCULAR DISEASE; CHEMICAL ANALYSIS; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; ELDERLY CARE; FEMALE; HUMAN; HYPERCALCEMIA; HYPERTENSION; NEUROPSYCHIATRY; OSTEOPENIA; PRIMARY HYPERPARATHYROIDISM; PSYCHOTHERAPY; SYMPTOMATOLOGY; DISEASE COURSE; HYPERPARATHYROIDISM; METABOLIC BONE DISEASE; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BONE DISEASES, METABOLIC; COGNITION DISORDERS; DIPHOSPHONATES; DISEASE PROGRESSION; DIURETICS; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; IMIDAZOLES; NERVOUS SYSTEM DISEASES; SODIUM CHLORIDE; TREATMENT OUTCOME;

EID: 21244494719     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03337723     Document Type: Article

References (22)

1. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000; 343: 1863-75.
2. Kearns AE, Thompson GB. Medical and surgical management of hyperparathyroidism. Mayo Clin Proc 2002; 77: 87-91.
3. Silverberg SJ, Bilezikian JP, Bone HG, Talpos GB, Horwitz MJ, Stewart AF. Therapeutic controversies in primary hyperparathyroidism. To treat or not to treat: conclusions from the NIH consensus conference. J Clin Endocrinol Metab 1999; 84: 2275-8.
4. Bilezikian JP, Potts JT, Fuleihan GE, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87: 5353-61.
5. Bilezikian JP, Silverberg SJ. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004; 350: 1746-51.
6. Bataille P, Achard JM, Fournier A, et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39: 1193-205.
7. Kebebew E, Duh QY, Clark O. Parathyroidectomy for primary hyperparathyroidism in octagenarians and nonagenarians. A plea for early surgical referral. Arch Surg 2003; 138: 867-71.
8. Conroy S, Moulias S, Wassif W. Primary hyperparathyroidism in the older person. Age Ageing 2003; 32: 571-8.
9. Watson LC, Marx CE. New onset of neuropsychiatric symptoms in the elderly: possible primary hyperparathyroidism. Psychosomatics 2002; 43: 413-7.
10. Roche NA, Young AE. Role of surgery in mild primary hyperparathyroidism in the elderly. Br J Surg 2000; 87: 1640-9.
11. Formiga F, Mascaró J, Chivite D, Pujol R. Reversibile dementia due to two coexisting diseases. Lancet 2000; 355: 1154.
12. Mc Donald CA, Bruce DG, Smith DJ. Primary hyperparathyroidism in an elderly woman: surgical reversibility of profound mental state problems due to mild hypercalcemia. Int J Geriatr Psychiatry 2002; 17: 601-3.
13. Silvenberg DJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999b; 107: 561-7.
14. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341: 1249-55.
15. Ohrvall U, Akeström G, Ljunghall S, Lundgren E, Juhlin C, Rastad J. Surgery for sporadic hyperparathyroidism in the elderly. World J Surg 1994; 18: 612-8.
16. Chigot JP, Menegaux F, Achrafi H. Should primary hyperparathyroidism be treated surgically in elderly patients older than 75 years? Surgery 1995; 117: 397-401.
17. Chen H, Parkerson S, Udelsman R. Parathyroidectomy in the elderly: do the benefits outweigh the risks? Worl J Surg 1998; 22: 531-6.
18. Ammann P, Herter-Clavel C, Lubrano A, Rizzoli R. A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism. Aging Clin Exp Res 2003; 15: 500-4.
19. Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res 2001; 16: 113-9.
20. Horiuchi T, Onouchi T, Inoue J, Shionoiri A, Hosoi T, Orimo H. A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy. Gerontology 2002; 48: 1031-8.
21. Body JJ. Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis. Exp Opin Pharmacother 2003; 4: 567-80.
22. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 2003; 25: 2669-708.